The anti-depression effect of Xylaria nigripes in patients with epilepsy: A multicenter randomized double-blind study

Peng, Wei; Wang, Xin; Hong, Zhen; Zhu, Guo Xing; Li, Bing Mei; Li, Ze; Ding, Mei; Geng, Zhi; Jin, Zheng; Miao, Lei; Wu, Li; Zhan, Shao

doi:10.1016/j.seizure.2015.03.014

Cited by 32 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Cochrane Review on this subject highlighted that the level of evidence is still low due to the poor quality of available studies [77]. In fact, there are only two randomized controlled trials for depression in epilepsy, the first, published more than 30 years ago, comparing nomifensine, amitriptyline and placebo [78] and the second investigating the antidepressant effect of a traditional Chinese medicine remedy, Xylaria Nigripes, as compared to placebo [79]. Both studies are significantly underpowered as the first study involved only 45 patients while the second one 104.…”

Section: Antidepressantsmentioning

confidence: 99%

Developments in depression in epilepsy: screening, diagnosis, and treatment

Mula

2019

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Introduction: Depression is one of the most frequent comorbidities in epilepsy affecting between 17% and 22% of patients but it is still underdiagnosed and undertreated. Areas covered: This paper discusses recent advances about screening, diagnosis and treatment of depression in epilepsy taking into account the heterogeneity of clinical scenarios where depression can occur. Expert opinion: A number of screening instruments are now validated for adults with epilepsy and their psychometric properties are discussed but the NDDIE is the most practical and cost-effective. Challenges in diagnosing depression in epilepsy are discussed including reasons for the atypical features of mood disorders in epilepsy. Psychological treatments and/or SSRIs are indicated but the level of evidence is still low. Even if there is no reason to hypothesis that internationally accepted guidelines of treatment of depression outside epilepsy may not be valid, rigorous studies are needed in order to have proper outcome measures. Epilepsy centers should have well-defined care pathways for depression in order to provide access to mental health support when needed.

show abstract

Section: Antidepressantsmentioning

confidence: 99%

Developments in depression in epilepsy: screening, diagnosis, and treatment

Mula

2019

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Wuling capsule was beneficial for treating post-stroke depression (PSD) when solely used or combined with standard antidepressants [Deanxit (flupentixol þmelitracen), Fluoxetine, Sertraline, Paroxetine or Citalopram] (Peng et al, 2014). Wuling capsule also improved the co-morbid depression in patients with epilepsy (Peng et al, 2015). However, the anti-depressive effects of Wuling powder and the underlying mechanism were poorly understood.…”

Section: Introductionmentioning

confidence: 99%

Wuling powder prevents the depression-like behavior in learned helplessness mice model through improving the TSPO mediated-mitophagy

Zheng

Wang

et al. 2016

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…The study showed that wuling capsules (three tablets, three times daily for 12 weeks) alleviated depressive symptoms in patients with epilepsy, and enhanced some aspects of quality of life without increasing the risk of exacerbating epileptic seizures. 87 …”

Section: Resultsmentioning

confidence: 99%

“…Wuling capsules are a safe drug with mild side effects, including diarrhea, dry mouth, dizziness, fatigue, abdominal discomfort, elevated liver enzymes, constipation, increased saliva, anterior thoracic discomfort, skin rash, and sneezing. 87 , 94…”

Section: Resultsmentioning

confidence: 99%

Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review

Feng

Tang

Lin

et al. 2016

NDT

View full text Add to dashboard Cite

Depression is a major mental disorder, and is currently recognized as the second-leading cause of disability worldwide. However, the therapeutic effect of antidepressants remains unsatisfactory. For centuries, Chinese herbal formulas (CHFs) have been widely used in the treatment of depression, achieving better therapeutic effects than placebo and having fewer side effects than conventional antidepressants. Here, we review the ethnopharmacology, phytochemistry, and pharmacology studies of nine common CHFs: “banxia houpo” decoction, “chaihu shugansan”, “ganmaidazao” decoction, “kaixinsan”, “shuganjieyu” capsules, “sinisan”, “wuling” capsules, “xiaoyaosan”, and “yueju”. Eight clinical trials and seven meta-analyses have supported the theory that CHFs are effective treatments for depression, decreasing Hamilton Depression Scale scores and showing few adverse effects. Evidence from 75 preclinical studies has also elucidated the multitarget and multipathway mechanisms underlying the antidepressant effect of the nine CHFs. Decoctions, capsules, and pills all showed antidepressant effects, ranked in descending order of efficacy. According to traditional Chinese medicine theory, these CHFs have flexible compatibility and mainly act by soothing the liver and relieving depression. This review highlights the effective treatment choices and candidate compounds for patients, practitioners, and researchers in the field of traditional Chinese medicine. In summary, the current evidence supports the efficacy of CHFs in the treatment of depression, but additional large-scale randomized controlled clinical trials and sophisticated pharmacology studies should be performed.

show abstract

The anti-depression effect of Xylaria nigripes in patients with epilepsy: A multicenter randomized double-blind study

Abstract: Xylaria nigripes could alleviate depressive symptoms within 12 weeks treatment and was well tolerated in patients with epilepsy.

Cited by 32 publications

References 29 publications

Developments in depression in epilepsy: screening, diagnosis, and treatment

Developments in depression in epilepsy: screening, diagnosis, and treatment

Wuling powder prevents the depression-like behavior in learned helplessness mice model through improving the TSPO mediated-mitophagy

Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review

Contact Info

Product

Resources

About